Developer site: The content shown here is test data.

MyEClinic
MyEClinic
Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.

Back to skin conditions

MAP3K7

Introduction

Main article: MAP kinase kinase kinase

Mitogen-activated protein kinase kinase kinase 7 (MAP3K7), also known as TAK1, is an enzyme that in humans is encoded by the MAP3K7 gene.[1]

Function

Function

The protein encoded by this gene is a member of the serine/threonine protein kinase family. This kinase mediates the signaling transduction induced by TGF beta and morphogenetic protein (BMP), and controls a variety of cell functions including transcription regulation and apoptosis. TAK1 is a central regulator of cell death and is activated through a diverse set of intra- and extracellular stimuli. TAK1 regulates cell survival not solely through NF-κB but also through NF-κB-independent pathways such as oxidative stress and receptor-interacting protein kinase 1 (RIPK1) kinase activity-dependent pathway.[2] In response to IL-1, this protein forms a kinase complex including TRAF6, MAP3K7P1/TAB1 and MAP3K7P2/TAB2; this complex is required for the activation of nuclear factor kappa B. This kinase can also activate MAPK8/JNK, MAP2K4/MKK4, and thus plays a role in the cell response to environmental stresses. Four alternatively spliced transcript variants encoding distinct isoforms have been reported.[3]

Interactions

Interactions

MAP3K7 has been shown to interact with:

References

References

  1. ↑ Kondo M, Osada H, Uchida K, Yanagisawa K, Masuda A, Takagi K, Takahashi T, Takahashi T (February 1998). “Molecular cloning of human TAK1 and its mutational analysis in human lung cancer”. Int J Cancer. 75 (4): 559–63. doi:10.1002/(SICI)1097-0215(19980209)75:4<559::AID-IJC11>3.0.CO;2-4. PMID 9466656.
  2. ↑ Mihaly, S. R.; Ninomiya-Tsuji, J.; Morioka, S. (2014-11-01). “TAK1 control of cell death”. Cell Death & Differentiation. 21 (11): 1667–1676. doi:10.1038/cdd.2014.123. ISSN 1350-9047. PMC 4211365. PMID 25146924.
  3. ↑ “Entrez Gene: MAP3K7 mitogen-activated protein kinase kinase kinase 7”.
  4. ↑ 4.0 4.1 Mochida Y, Takeda K, Saitoh M, Nishitoh H, Amagasa T, Ninomiya-Tsuji J, Matsumoto K, Ichijo H (October 2000). “ASK1 inhibits interleukin-1-induced NF-kappa B activity through disruption of TRAF6-TAK1 interaction”. J. Biol. Chem. 275 (42): 32747–52. doi:10.1074/jbc.M003042200. PMID 10921914.
  5. ↑ 5.0 5.1 5.2 5.3 Ninomiya-Tsuji J, Kishimoto K, Hiyama A, Inoue J, Cao Z, Matsumoto K (March 1999). “The kinase TAK1 can activate the NIK-I kappaB as well as the MAP kinase cascade in the IL-1 signalling pathway”. Nature. 398 (6724): 252–6. doi:10.1038/18465. PMID 10094049.
  6. ↑ Sakurai H, Miyoshi H, Toriumi W, Sugita T (April 1999). “Functional interactions of transforming growth factor beta-activated kinase 1 with IkappaB kinases to stimulate NF-kappaB activation”. J. Biol. Chem. 274 (15): 10641–8. doi:10.1074/jbc.274.15.10641. PMID 10187861.
  7. ↑ 7.0 7.1 Sakurai H, Miyoshi H, Mizukami J, Sugita T (June 2000). “Phosphorylation-dependent activation of TAK1 mitogen-activated protein kinase kinase kinase by TAB1”. FEBS Lett. 474 (2–3): 141–5. doi:10.1016/s0014-5793(00)01588-x. PMID 10838074.
  8. ↑ 8.0 8.1 8.2 Ishitani T, Takaesu G, Ninomiya-Tsuji J, Shibuya H, Gaynor RB, Matsumoto K (December 2003). “Role of the TAB2-related protein TAB3 in IL-1 and TNF signaling”. EMBO J. 22 (23): 6277–88. doi:10.1093/emboj/cdg605. PMC 291846. PMID 14633987.
  9. ↑ Wang C, Deng L, Hong M, Akkaraju GR, Inoue J, Chen ZJ (July 2001). “TAK1 is a ubiquitin-dependent kinase of MKK and IKK”. Nature. 412 (6844): 346–51. doi:10.1038/35085597. PMID 11460167.
  10. ↑ 10.0 10.1 10.2 Cheung PC, Nebreda AR, Cohen P (February 2004). “TAB3, a new binding partner of the protein kinase TAK1”. Biochem. J. 378 (Pt 1): 27–34. doi:10.1042/BJ20031794. PMC 1223947. PMID 14670075.
  11. ↑ Channavajhala PL, Wu L, Cuozzo JW, Hall JP, Liu W, Lin LL, Zhang Y (November 2003). “Identification of a novel human kinase supporter of Ras (hKSR-2) that functions as a negative regulator of Cot (Tpl2) signaling”. J. Biol. Chem. 278 (47): 47089–97. doi:10.1074/jbc.M306002200. PMID 12975377.
  12. ↑ 12.0 12.1 Takaesu G, Kishida S, Hiyama A, Yamaguchi K, Shibuya H, Irie K, Ninomiya-Tsuji J, Matsumoto K (April 2000). “TAB2, a novel adaptor protein, mediates activation of TAK1 MAPKKK by linking TAK1 to TRAF6 in the IL-1 signal transduction pathway”. Mol. Cell. 5 (4): 649–58. doi:10.1016/s1097-2765(00)80244-0. PMID 10882101.
  13. ↑ 13.0 13.1 Takaesu G, Ninomiya-Tsuji J, Kishida S, Li X, Stark GR, Matsumoto K (April 2001). “Interleukin-1 (IL-1) receptor-associated kinase leads to activation of TAK1 by inducing TAB2 translocation in the IL-1 signaling pathway”. Mol. Cell. Biol. 21 (7): 2475–84. doi:10.1128/MCB.21.7.2475-2484.2001. PMC 86880. PMID 11259596.
  14. ↑ Kimura N, Matsuo R, Shibuya H, Nakashima K, Taga T (June 2000). “BMP2-induced apoptosis is mediated by activation of the TAK1-p38 kinase pathway that is negatively regulated by Smad6”. J. Biol. Chem. 275 (23): 17647–52. doi:10.1074/jbc.M908622199. PMID 10748100.
  15. ↑ Yanagisawa M, Nakashima K, Takeda K, Ochiai W, Takizawa T, Ueno M, Takizawa M, Shibuya H, Taga T (December 2001). “Inhibition of BMP2-induced, TAK1 kinase-mediated neurite outgrowth by Smad6 and Smad7”. Genes Cells. 6 (12): 1091–9. doi:10.1046/j.1365-2443.2001.00483.x. PMID 11737269.
  16. ↑ Hanada M, Ninomiya-Tsuji J, Komaki K, Ohnishi M, Katsura K, Kanamaru R, Matsumoto K, Tamura S (February 2001). “Regulation of the TAK1 signaling pathway by protein phosphatase 2C”. J. Biol. Chem. 276 (8): 5753–9. doi:10.1074/jbc.M007773200. PMID 11104763.
  17. ↑ Walsh MC, Kim GK, Maurizio PL, Molnar EE, Choi Y. Unutmaz D, ed. “TRAF6 autoubiquitination-independent activation of the NFkappaB and MAPK pathways in response to IL-1 and RANKL”. PLoS ONE. 3 (12): e4064. doi:10.1371/journal.pone.0004064. PMC 2603309. PMID 19112497.
  18. ↑ Sorrentino A, Thakur N, Grimsby S, Marcusson A, von Bulow V, Schuster N, Zhang S, Heldin CH, Landström M (October 2008). “The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner”. Nat. Cell Biol. 10 (10): 1199–207. doi:10.1038/ncb1780. PMID 18758450.
Further reading

Further reading